Ọrịa kansa ọbara Lymphoblastic dị oke njọ (T-ALL)-09

Otu nwa akwụkwọ mahadum aha ya bụ Mengmeng si Yanjiao, Guizhou, natara ọgwụgwọ dị irè na BIOOCUS Medical Group.

Mengmeng, nwanyị dị afọ iri abụọ na otu, pụtara n'ụlọ ọgwụ anyị na-anaghị ahụ maka ndị ọrịa na June 22, 2021, na-enwe ike ọgwụgwụ mgbe niile. Nnwale ọbara gosiri na ọ nwere ike 479×10^9/L. Nnwale ọkpụkpụ ndị ọzọ gosiri na ọ nwere ọrịa leukemia lymphoblastic dị oke njọ (ụdị T-cell subtype). O mere usoro chemotherapy ugboro abụọ, mana leukemia anaghị anabata ya, ebe MRD (ọrịa fọdụrụnụ pere mpe) dị 56.01%, o nwekwara ọrịa leukemia sistemụ akwara etiti.

Na Ọgọst 13, a chịkọtara sel lymphocytes autologous ma nye ha chemotherapy. Na Ọgọst 30, Mengmeng natara CD7 CAR-T cell infusion. Izu abụọ ka e tinyere ya, nyocha ọkpụkpụ gosiri na e wepụrụ ya kpamkpam, enweghị mmetụta MRD, na njikwa leukemia sistemụ akwara etiti. O nwetara mmeghachi omume cytokine release syndrome (CRS) nke ọkwa 1 na-enweghị mmeghachi omume ọjọọ na sistemụ akwara etiti.